Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




First-Ever POC Analyzer Reads Patient's Immune System to Detect Diseases Before Symptoms Present

By LabMedica International staff writers
Posted on 19 May 2023

Each year, sepsis affects over 50 million individuals worldwide and accounts for nearly 20% of all fatalities. More...

Additionally, sepsis poses a substantial economic strain, with projected costs exceeding USD 62 billion annually in the U.S. alone. However, rapid diagnosis and treatment could potentially prevent up to 80% of sepsis-related deaths. Now, a breakthrough point-of-care diagnostic platform that leverages the power of the human immune system is poised to address the two main challenges associated with sepsis: broad screening and rapid identification.

Immune Reveal, a first-of-its-kind point-of-care diagnostic platform, is a collaborative creation of Immune IQ (Twin Cities, MN, USA) and Honeywell (Charlotte, NC, USA). This groundbreaking platform integrates automatic disease screening with confirmatory tests to rapidly offer unique insights into various diseases, such as sepsis, heart disease, cancer, and COVID-19. The Immune Reveal platform offers diagnostic information quicker and more cost-effectively than ever before. With one of the most powerful data sets in the industry and the incorporation of artificial intelligence within its system, Immune Reveal could redefine the standard of care in diagnosis and treatment.

Immune Reveal generates one of the industry's most powerful data sets, which, when translated by artificial intelligence, can " read " diseases that a patient's immune system has detected even before the appearance of symptoms. This game-changing approach paves the way for a new era of integrated tests that can perform disease screening, confirmation testing, and precision treatment testing in minutes using the same card and sample. Immune IQ plans to commercialize sepsis detection as the initial test on the Immune Reveal platform. A recent clinical study successfully showcased Immune Reveal's ability to consistently generate a large cellular dataset. The combination of this data has been independently demonstrated in peer-reviewed publications to yield highly accurate sepsis detection.

"The human immune system is widely recognized as a near-perfect tool for detecting disease, even far in advance of noticeable symptoms. Immune Reveal is the first platform that can both read and decode the immune system's data in as soon as five minutes," said Immune IQ founder and CEO, David Deetz.

Related Links:
Immune IQ
Honeywell


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Procalcitonin Test
LIAISON B•R•A•H•M•S PCT II GEN
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.